Integrating the Healthcare Enterprise



5

IHE Quality, Research and Public Health (QRPH)

Technical Framework Supplement

10

Drug Safety Content (DSC)

15

Trial Implementation

20

Date: September 24, 2012

Author: IHE QRPH Technical Committee

Email: qrph@ihe.net

IHE Quality, Research and Public Health Technical Framework Supplement – Drug Safety Content (DSC)

Foreword

This is a supplement to the IHE Quality, Research and Public Health Technical Framework V0.1. Each supplement undergoes a process of public comment and trial implementation before being incorporated into the volumes of the Technical Frameworks.

- This supplement is published for Trial Implementation on September 24, 2012 and may be available for testing at subsequent IHE Connectathons. The supplement may be amended based on the results of testing. Following successful testing it will be incorporated into the Quality, Research and Public Health Technical Framework. Comments are invited and may be submitted at http://www.ihe.net/qrph/qrphcomments.cfm.
- This supplement describes changes to the existing technical framework documents and where indicated amends text by addition (**bold underline**) or removal (**bold strikethrough**), as well as addition of new sections introduced by editor's instructions to "add new text" or similar, which for readability are not bolded or underlined.
- "Boxed" instructions like the sample below indicate to the Volume Editor how to integrate the relevant section(s) into the relevant Technical Framework volume:

Replace Section X.X by the following:

General information about IHE can be found at: www.ihe.net

Information about the IHE Quality, Research and Public Health domain can be found at: http://www.ihe.net/Domains/index.cfm

Information about the structure of IHE Technical Frameworks and Supplements can be found at: http://www.ihe.net/About/process.cfm and http://www.ihe.net/profiles/index.cfm

The current version of the IHE Technical Framework can be found at:

50 http://www.ihe.net/Technical Framework/index.cfm

CONTENTS

5	5
J	J

	INTRODUCTION TO THIS SUPPLEMENT	4
	OPEN ISSUES AND QUESTIONS	
	CLOSED ISSUES VOLUME 1 – PROFILES	
<i>(</i> 0		
60	COPYRIGHT PERMISSION	
	X.1 DSC Actors, Transactions, and Content Modules	
	X.1.1 Actor Descriptions and Actor Profile Requirements	7
<i>-</i>	X.2 DSC ACTOR OPTIONS	
65	X.3 DSC ACTOR REQUIRED GROUPINGS	
	X.4 DSC OVERVIEW	
	X.5 DSC Security Considerations	
	X.5.1 Consistent Time (CT)	
70	X.5.2 Audit Trail and Node Authentication (ATNA)	
	X.5.3 Cross Enterprise User Authentication (XUA)	
	APPENDICES	
	ACTOR SUMMARY DEFINITIONS	
75	TRANSACTION SUMMARY DEFINITIONS	
13	GLOSSARY	
	VOLUME 2 – TRANSACTIONS	
	5 AUDIT SECURITY MESSAGES	
00	5.Z3 AUDIT RECORD CONSIDERATIONS	
80	5.Z3.1 Retrieve Form ([ITI-34]) audit messages	
	5.Z3.3 Archive Form (111-35]) adati messages	
	5.Z3.4 Retrieve Clarifications	
	NAMESPACE ADDITIONS	25
85	VOLUME 3 – CONTENT MODULES	26
	6 HL7 V3 CDA CONTENT MODULES	27
	6.3.1 CDA Document Content Modules	27
	APPENDICES	52
	APPENDIX A: REFERENCE IMPLEMENTATION	52
90	A.1 Drug Safety Content CCD to E2B M Crosswalk	
	A.2 DRUG SAFETY CONTENT CCD TO E2B R3 CROSSWALK	
	APPENDIX B: TRIGGERS	
	VOLUME 4 – NATIONAL EXTENSIONS	106

Introduction to this Supplement

The Drug Safety Content Profile (DSC) describes the content and format to be used for the Prepopulation Data within the Retrieve Form transaction described within the Retrieve Form for Data Capture (RFD) Integration Profile. The purpose of this profile is to support a standard set of data in the Continuity of Care Document (CCD) format which the Form Filler provides for use in reporting adverse events as it relates to Drug Safety. In addition, some actors' groupings are added to enhance the security of DSC actors. More specifically, it defines the ATNA audit logs which are associated with each of the RFD transactions used in this profile, namely Retrieve Form [ITI-34], Submit Form [ITI-35] and Archive Form [ITI-36]. Finally, as potential reference implementation this profile will reference the ability to convert this output into the ICH E2B M standard.

Open Issues and Questions

None

Closed Issues

110 None

95

100

Volume 1 – Profiles

Copyright Permission

No additions

115

Domain-specific additions

No additions

X Drug Safety Content (DSC) Profile

The Drug Safety Content Profile (DSC) specifies a standard way to generate an adverse event document from EHR data provided in the CDA standard.

While the profile does not mandate the use of the ICH E2B standard, it provides guidance on how this profile could incorporate transformation of CDA content into E2B.

The profile uses the transaction framework defined in the RFD profile. It further constrains the prepopData data elements of the RFD Retrieve Form transaction in order to optimize the prepopulation of the form used to collect the data during a patient's visit on an investigation site and an optional functionality is more tightly specified as required.

Other FDA requirements which this profile meets are security requirements. This is enabled by the grouping of each of the actors defined in this profile with a CT time client actor, an ATNA secure node or application actor and an XUA X-service user actor.

In Summary, the DSC profile is just like the RFD profile except it is more specific about the prepopulation xml requirements used when retrieving a form, some optional functionality is more tightly specified as required and other actors groupings are added to enhance the security of the actors.

X.1 DSC Actors, Transactions, and Content Modules

Figure X.1-1 shows the actors directly involved in the DSC Profile and the relevant transactions between them. If needed for context, other actors that may be indirectly involved due to their participation in other related profiles are shown in dotted lines. Actors which have a mandatory grouping are shown in conjoined boxes.




Figure X.1-1: DSC Actor Diagram

140

Figure X.1-1 shows the principal actors described (bold and solid boxes) in the DSC Integration Profile. Here there are no transactions per se between these actors as this profile is a content profile, but if there were some, they would be designed in bold and solid lines. The diagram also shows actors which are not defined in this profile (dashed Boxes) but which SHALL be grouped with the principal ones.

As explained in the summary and shown in table X.3-1, the DSC actors SHALL also be grouped with some ATNA, XUA and CT actors. However, for clarity's sake, it was decided not to show them in figure X.1, as this figure points out the most important features which this profile is about. An exhaustive DSC actor diagram can be found in the volume 1 appendices (Figure X.1-2)

Table X.1-1 lists the transactions for each actor directly involved in the DSC Profile. In order to claim support of this Profile, an implementation of an actor must perform the required transactions (labeled "R") and MAY support the optional transactions (labeled "O"). Actor groupings are further described in Section X.3.

155

145

150

Table X.1-1: DSC Profile - Actors and Transactions

Actors	Transactions	Optionality	Section in Vol. 2
Form Filler	Retrieve Form	R	ITI TF-2b: 3.34
	Submit Form	R	ITI TF-2b: 3.35
	Archive Form	0	ITI TF-2b: 3.36
Form Manager	Retrieve Form	R	ITI TF-2b: 3.34
Form Receiver	Submit Form	R	ITI TF-2b: 3.35
Form Archiver	Archive Form	R	ITI TF-2b: 3.36

Table X.1-2: DSC Profile - Actors and Content Modules

Actors	Content Module	Optionality	Section in Vol. 3
Form Filler	Case Report Document (creator)	R	3.Y1
Form Manager	Case Report Document (consumer)	R	3.Y1
Form Receiver	None	N/A	N/A

160 X.1.1 Actor Descriptions and Actor Profile Requirements

Normative requirements are typically documented in Volume 2 (Transactions) and Volume 3 (Content Modules). Some Integration Profiles, however, contain requirements which link transactions, data, and/or behavior. Those Profile requirements are documented in this section as normative requirements ("shall").

165 **X.1.1.1 Form Filler**

In addition to its role as defined in the RFD profile in ITI TF-1, the Form Filler SHALL support the generation of the pre-population data as defined in Volume 3, content requirements, hereafter named "Case Report Document."

As described in table X.3-1, for security enhancing purposes, the Form Filler SHALL also be grouped with a CT Time Client, a XUA X-Service Provider, and an ATNA Secure Node or ATNA Secure Application.

X.1.1.2 Form Manager

In addition to its role as defined in the RFD profile in ITI TF-1, the Form Manager MAY specify mappings between CCD and E2B. While the profile does not mandate the use of the E2B standard, it provides guidance on how this profile could incorporate transformation of CDA content into E2B.

As described in table X.3-1, for security enhancing purposes, the Form Manager actor SHALL also be grouped with a CT Time Client, a XUA X-Service Provider, and an ATNA Secure Node or ATNA Secure Application.

180 X.1.1.3 Form Receiver

175

The role of the Form Receiver in this profile is the one defined in the RFD profile in ITI TF-1.

It SHALL also be grouped with a CT Time Client, a XUA X-Service Provider, and an ATNA Secure Node or ATNA Secure Application.

X.1.1.4 Form Archiver

The role of the Form Archiver in this section is the one defined in the RFD profile in ITI TF-1. It SHALL also be grouped with a CT Time Client, a XUA X-Service Provider, and an ATNA Secure Node or ATNA Secure Application.

X.2 DSC Actor Options

Options that may be selected for this Profile are listed in the table X.2-1 along with the Actors to which they apply. Dependencies between options when applicable are specified in notes.

Actor	Options	Volume & Section
Form Filler	Archive Form	ITI TF-2b:3.36
Form Manager	None	-
Form Receiver	None	-
Form Archiver	None	-

Table X.2-1: DSC Profile - Actors and Options

Note: Considering that we are in the DSC profile, the pre-population data is not an option anymore; it is required as the profile is precisely about defining it. The DSC Profile requires that this prepop data conforms to the xml data constrained in its volume 3.

X.3 DSC Actor Required Groupings

Actor(s) which are required to be grouped with another Actor(s) are listed in this section. The grouped Actor may be from this profile or a different domain/profile. These mandatory required groupings, plus further descriptions if necessary, are given in the table below.

An Actor from this profile (Column 1) must implement all of the required transactions in this profile in addition to all of the required transactions for the grouped profile/actor listed (Column 2).

Table X.3-1: Drug Safety Content - Actors Required Groups

DSC Actor	Actor to be grouped with	Technical Framework Reference	Note
Form Filler	ATNA Secure Node or ATNA Secure Application	ITI TF- 1: 9.4	Required
	CT Time Client	ITI TF- 1: 7.1	Required
	XUA X-Service User	ITI TF- 1: 13.4	Required
Form Manager	ATNA Secure Node or ATNA Secure Application	ITI TF- 1: 9.4	Required
	CT Time Client	ITI TF- 1: 7.1	Required
	XUA X-Service Provider	ITI TF- 1: 13.4	Required
Form Receiver	ATNA Secure Node or ATNA Secure Application	ITI TF- 1: 9.4	Required
	CT Time Client	ITI TF- 1: 7.1	Required
	XUA X-Service Provider	ITI TF- 1: 13.4	Required
Form Archiver	ATNA Secure Node or ATNA Secure Application	ITI TF- 1: 9.4	Required
	CT Time Client	ITI TF- 1: 7.1	Required
	XUA X-Service Provider	ITI TF- 1: 13.4	Required

205

195

X.4 DSC Overview

X.4.1 Concepts

Not applicable

X.4.2 Use Case #1: Clinical Trial Adverse Event (AE) Reporting

This use case demonstrates how the DSC profile can be used to report an adverse event in the context of a clinical trial.

X.4.2.1 Clinical Trial Adverse Event (AE) Reporting Use Case Description

A physician, Dr. Smith, is seeing his first clinical trial patient, Rita Jones, for her trial visit. As he talks to her he is reviewing her clinical data in the clinical trial management software used by his practice. After discussing her progress over the last two weeks on the trial, she describes a pain in her abdomen that wasn't present until she started the trial drug for her heart condition. Dr. Smith notices an unanticipated increase in her amylase level and decides this could be due to the trial drug, as this is the second case with similar symptoms he's seen in the last week.

- He chooses a menu item from the software to 'Report AE" and a form appears in which he selects the information to include in the report. Ms. Jones' labs, medications, demographics, physical exam and current complaint information are added into the form automatically. Dr. Smith adds some additional information on his suspicions in a text box on the form and pushes 'Report this AE", and the form disappears from his screen.
- Dr. Smith recalls the time prior to using the automated reporting process, and remembers how he would want to report an event like this, but after finishing seeing his patients, doing paperwork and getting lunch, he would only remember a few of the case details, and he never remembered where he could find a copy of the form to report the event. If he ran into his study nurse he would tell her the bare details of the case and ask her to report it, but that was as much as he was able to do given his schedule.
- With this new system, he was confident that the case had the relevant clinical information, and he could add his interpretation of the case during the patient visit, while the impressions were fresh in his mind. The entire process usually took him only a few minutes to complete and he knew that the report would be complete and of high quality. He also knew that he could call the report up whenever he wished to review it in light of new information or similar cases.

X.4.2.2 Clinical Trial Adverse Event Process Flow




Figure X.4.2.2-1: Basic Process Flow in DSC Profile used in the context of a Clinical Trial Adverse Event Reporting

X.4.2.3 Current State

Currently in the U.S., Europe, and Japan, adverse drug events (ADEs) and adverse drug reactions (ADRs), here generally referred to as adverse events (AEs), are collected on drugs (here meant to include both exogenous chemical and endogenous or 'biologics') through all phases of clinical trials and after the drug has been approved for marketing, through to the life of the drug on the market. There are some differences in regulations, practices and systems by geographic region, but certain commonalities remain:

Clinical Trial

255

245

250

240

• During clinical trial (CT) investigations, objectives include AEs as a safety component, one aspect of which is the reporting out of AEs during the trial. Certain types of AEs, classified as 'serious' by regulatory definition, must be reported according to a strict timeline and cannot wait until the completion of the trial. Data and information on these events must be

collected, evaluated and sent to regulatory authorities by the principal investigator in a timely fashion. Currents methods of reporting range from a completion of a simple paper form by the principal investigator or a designee based on data captured in case record forms, visits and phone calls with medical personnel, to initial population of data directly from trial management systems and electronic health records (EHRs) used at the trial sites followed by assessment and refining of the information by designated personnel. A significant issue with all AE reporting from clinical trials involves the myriad number of clinical data storage systems, standards and data mappings and translations needed to get the data from the parent system to the regulators in a timely fashion.

270 **Phase IV Trial**

285

290

295

300

- One frequent source of post-marketing AEs comes from trials undertaken once the drug is on the market. These trials can range from Phase IV trials in which there is some type of case control or other means of control and a formal protocol to more loosely controlled trials (commonly referred to as 'marketing trials' in which there is a very general protocol). Phase IV trials are often performed to test the safety and effectiveness of new indications for drugs approved for more limited clinical use. The more well-controlled the trial, the more the data collection and reporting requirements resemble that of pre-marketing CTs. But in marketing trials, data may be collected from various means through phone interviews, surveys, emails, and from a very large number of consumers/patients. In these trials the quality and amount of data collection can vary tremendously.
 - A common thread in all AE reporting is the heterogeneity of the systems and stakeholders in the process. This creates a large number of possible forms, interfaces and data translation requirements which increase the friction between the participants from the original reporter all the way through to the regulator.
 - The current post marketing reporting process in the U.S. is largely paper-based and requires people to track down paper or .pdf forms which take anywhere from 30 to 45 minutes to complete. In Europe some countries have specialized reporting of AEs from, e.g., general practitioners, but there are common technological challenges with maintaining reporting forms and decreasing the burden of producing a report remains problematic. In other countries the process is similar to the U.S., with similar issues. Beyond the initial report, because of the number of handoffs in the process, the different requirements of the various data processing systems involved, and the various requirements for data privacy, a standardized means of defining and moving data through the process is also needed a commonly recognized format and process can greatly improve how post marketing reports are created and received in the future. Such transmission, privacy and security concerns are not in the direct scope of this profile which specifically addresses the content of the message.

X.4.2.4 Desired State

Given the heterogeneous environment for AE collection and reporting, it is highly desirable to provide some more efficient way to move the data through the reporting system so that the act of

reporting becomes easier as a routine output of usual clinical care processes, data fidelity can be maintained, reporting can be timely, and the number of translations of data that occur can be reduced to a minimum.

In clinical trials, an investigator should be able to use a single process to report AEs across any
CTs, and should not have to remember or transcribe data that already exists in the clinical
systems. Additionally, to improve the reporting process, maintenance of data required for
reporting should be accomplished without modification of each underlying data source system,
especially given the large number of systems used in generating the data at the sites, in managing
the trials, in processing the data at the manufacturers, and in receiving the data at the regulators
Standardization of data collection instruments and avoidance of duplicate data entry and
transcription is similarly a desire for post marketing trials.

X.4.3 Use Case #2: Post-Market Surveillance AE Reporting

This use case demonstrates how the DSC profile can be used to report an adverse event in the context of post-market surveillance.

315 X.4.3.1 Post-Market Surveillance AE Reporting Use Case Description

In the afternoon, when he was seeing the ambulatory clinic patients, Dr. Smith discussed with Mr. Brown the muscle weakness and shooting pains in his legs that started a few days after being put on his high dose statin regimen following his angioplasty. Dr. Smith thought it was likely related to the statin and after counseling Mr. Brown, Dr. Smith pulled up his record in the EHR used by his practice, discontinued the statin, and marked reason for discontinuation as "AE". This brought up a pre-populated form with Mr. Brown's demographics, current labs, medical history, medications and a text box labeled "Adverse Event". Dr. Smith typed in 'myopathy' and noted that the generic and trade name of the statin was pre-populated in the form. He added a note that he had ordered tests to help confirm the diagnosis and they were pending. He then pressed the "Submit AE" button on the form and it disappeared, and Dr. Smith finished ordering tests and writing his notes on Mr. Brown in the EHR.

Dr. Smith remembered how he never previously considered reporting an AE from one of his patients since it involved finding a reporting form, filling out the information himself and usually being late to see his next patient. And if he would ask a nurse or pharmacist to file a report he knew the report would rarely, if ever, be submitted. With this new process he could complete the report himself and not have to pass along the burden to someone else.

335

X.4.3.2 Clinical Trial Adverse Event Process Flow




Figure X.4.3.2-1: Basic Process Flow in DSC Profile used in the context of a Post-Marketing Surveillance Adverse Event Reporting

X.4.3.3 Current State

Currently in the U.S., Europe, and Japan, adverse drug events (ADEs) and adverse drug reactions (ADRs), here generally referred to as adverse events (AEs), are collected on drugs (here meant to include both exogenous chemical and endogenous or 'biologics') through all phases of clinical trials and after the drug has been approved for marketing, through to the life of the drug on the market. There are some differences in regulations, practices and systems by geographic region, but certain commonalities remain:

Once a drug is on the market, AEs are collected through various means, but in general the common state of affairs is through a paper-based system of reporting. In some cases reporting initiates from phone calls to a drug information center sponsored by a drug manufacturer from consumers taking the medication, doctors caring for patients or other healthcare personnel such as pharmacists. The information is transcribed by the call center personnel and forwarded on to the manufacturer. In other situations the consumer or healthcare practitioner may call the FDA directly or may send in a paper form through the postal service or by fax, to report the event. In the U.S. a MedWatch® form can be

340

345

used for this purpose. ¹ In all cases of post-marketed reporting, getting the data from the system in which it resides (e.g., EHR) into a form which is ready to be received by regulatory authorities is a laborious process and not part of any clinical routine. This 'burden of reporting' likely has a significant role in the number of difficulties seen in post marketing reporting of AEs which include a lack of quality in reports, a small number of reports, and a general difficulty in getting enough information in any one report to make an adequate assessment of the event(s) in question. In some countries this situation is improved through national systems and/or regulatory requirements for reporting, but in all cases the act of reporting can be made easier through a more direct flow of clinical information on the AE to the regulatory authorities and manufacturers.

X.4.3.4 Desired State

360

365

- Given the heterogeneous environment for AE collection and reporting, it is highly desirable to provide some more efficient way to move the data through the reporting system so that the act of reporting becomes easier as a routine output of usual clinical care processes, data fidelity can be maintained, reporting can be timely, and the number of translations of data that occur can be reduced to a minimum.
- The desired state for post-marketing reporting is one in which the burden to submit an AE report is very low, and is part of the routine of the reporter especially in the case of the physician or other healthcare practitioner. This same reasoning holds true if the reporter is a consumer or patient using a system to maintain their personal health information such as a Personal Health Record. In such post-marketing AE reporting, integrated reporting solutions should trigger and pre-populate essential information to the extent possible in standard formats. Such solutions should also enable behind the scene mapping of clinical care interface terminology through clinically interoperable formats directly to elements required for surveillance for medications and biologics in an integrated fashion.

X.5 DSC Security Considerations

385 X.5.1 Consistent Time (CT)

In order to address identified security risks all actors in DSC should be grouped with Consistent Time (CT) Profile – Time Client actor. This grouping will assure that all systems have a consistent time clock to assure a consistent timestamp for audit logging.

¹ MedWatch® is a voluntary AE reporting form from the US Food and Drug Administration (FDA) that can be used for online data entry, or printing and submission via fax or postal service. Information is available at: http://www.fda.gov/medwatch.

X.5.2 Audit Trail and Node Authentication (ATNA)

In order to address identified security risks all actors in DSC should be grouped with Audit Trail and Node Authentication (ATNA) profile – Secure Node actor or ATNA Secure Application actor. This grouping will assure that only highly trusted systems can communicate and that all changes are recorded in the audit log.

X.5.3 Cross Enterprise User Authentication (XUA)

In order to address identified security risks all actors in DSC should be grouped with Cross Enterprise User Authentication (XUA) profile actors as appropriate. This grouping will assure that only highly trusted persons can communicate.

X.6 DSC Cross Profile Considerations

Not applicable

Appendices

Actor Summary Definitions

Add the following terms to the IHE TF General Introduction Namespace list of Actors:

405

Transaction Summary Definitions

Add the following terms to the IHE TF General Introduction Namespace list of Transactions:

Actor/transaction diagram with security grouping




Figure X.1-2: DSC actor/transaction diagram with security grouping2

 $^{2\ {\}rm This}\ {\rm figure}\ {\rm is}\ {\rm for}\ {\rm informational}\ {\rm purposes}\ {\rm only}.$ It is not normative.

IHE Quality, Research and Public Health Technical Framework Supplement – Drug Safety Content (DSC)

Glossary

Add the following terms to the IHE Technical Frameworks General Introduction Glossary:

430 None

Volume 2 – Transactions

5 Audit Security Messages

435 **5.Z3 Audit Record Considerations**

5.Z3.1 Retrieve Form ([ITI-34]) audit messages

The Retrieve Form Transaction is PHI-Export event, as defined in ITI TF-2a: Table 3.20.6-1. The Actors involved in the transaction shall create audit data in conformance with DICOM (Supp 95) "Data Export"/"Data Import", with the following exceptions.

440 5.Z3.1.1 Form Filler audit message

	Field Name	Opt	Value Constraints
Event	EventID	M	EV(110106, DCM, "Export")
AuditMessage/ EventIdentification	EventActionCode	M	"R" (Read)
	EventDateTime	M	not specialized
	EventOutcomeIndicator	M	not specialized
	EventTypeCode	M	EV("ITI-34", "IHE Transactions", "Retrieve Form")
Source (Document Source) (1)			
Human Requestor (0n)			
Destination (Doc	ument Repository) (1)		
Audit Source (Do	ocument Source) (1)		
Patient (1)			
prepopData (1)			

Where:

Source	UserID	M	Host system name
AuditMessage/ ActiveParticipant	AlternativeUserID	M	the process ID as used within the local operating system in the local system logs.
	UserName	U	not specialized
	UserIsRequestor	M	"true"
	RoleIDCode	M	EV(110153, DCM, "Source")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.
Human	UserID	M	Identity of the human that initiated the transaction.
Requestor	AlternativeUserID	U	not specialized
(if known)	UserName	U	not specialized
AuditMessage/ ActiveParticipant	UserIsRequestor	M	"true"
	RoleIDCode	U	Access Control role(s) the user holds that allows this transaction.

NetworkAccessPointTypeCode	NA	
NetworkAccessPointID	NA	

Destination	UserID	M	SOAP endpoint URI.
AuditMessage/ ActiveParticipant	Alternative User ID	U	not specialized
7 iouvoi unitoipuni	UserName	U	not specialized
	UserIsRequestor	M	"false"
	RoleIDCode	M	EV(110152, DCM, "Destination")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.

445

Audit Source	AuditSourceID	U	Not specialized.
AuditMessage/ AuditSourceldentificati	AuditEnterpriseSiteID	U	not specialized
on	AuditSourceTypeCode	U	not specialized

Patient	ParticipantObjectTypeCode	M	"1" (Person)
(AuditMessage/	ParticipantObjectTypeCodeRole	M	"1" (Patient)
ParticipantObjectIde	1 3 31		
ntification)	ParticipantObjectDataLifeCycle	U	not specialized
	ParticipantObjectIDTypeCode	M	EV(2, RFC-3881, "Patient Number")
	ParticipantObjectSensitivity	U	not specialized
	PARTICIPANTOBJECTID	M	The subject ID in HL7 CX format.
	ParticipantObjectName	U	not specialized
	<i>PARTICIPANTOBJECTQUERY</i>	U	not specialized
	ParticipantObjectDetail	U	not specialized
prepopData	ParticipantObjectTypeCode	M	"2" (System)
(AuditMessage/ ParticipantObjectIde	ParticipantObjectTypeCodeRole	M	"20" (job)
ntification)	ParticipantObjectDataLifeCycle	U	not specialized
	ParticipantObjectIDTypeCode	M	EV(2, RFC-3881, "Document ID")
	ParticipantObjectSensitivity	U	not specialized
	PARTICIPANTOBJECTID	M	The prepopData Document unique ID
	ParticipantObjectName	U	not specialized
	PARTICIPANTOBJECTQUERY	U	not specialized
	ParticipantObjectDetail	U	not specialized

5.Z3.1.2 Form Manager audit message

	Field Name	Opt	Value Constraints
Event	EventID	M	EV(110107, DCM, "Import")

	EventActionCode	M	"C" (Create)		
	EventDateTime	M	not specialized		
	EventOutcomeIndicator	M	not specialized		
	EventTypeCode	M	EV("ITI-34", "IHE Transactions", "Retrieve Form")		
Source (Document Source) (1)					
Destination (Document Repository or Document Recipient) (1)					
Audit Source (Do	Audit Source (Document Repository or Document Recipient) (1)				
Patient (1)					
prepopData (1)					

Where:

Source	UserID	M	Host system name
AuditMessage/ ActiveParticipant	AlternativeUserID	U	not specialized
	UserName	U	not specialized
	UserIsRequestor	M	"false"
	RoleIDCode	M	EV(110153, DCM, "Source")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.

Destination	UserID	M	SOAP endpoint URI
AuditMessage/ ActiveParticipant	AlternativeUserID	M	the process ID as used within the local operating system in the local system logs.
	UserName	U	not specialized
	UserIsRequestor	M	"false"
	RoleIDCode	M	EV(110152, DCM, "Destination")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.

 Audit Source
 AuditSourceID
 U
 Not specialized.

 AuditMessage/AuditSourceIdentification
 AuditEnterpriseSiteID
 U
 not specialized

 AuditSourceTypeCode
 U
 not specialized

Patient	ParticipantObjectTypeCode	M	"1" (Person)
(AuditMessage/ ParticipantObjectIde	ParticipantObjectTypeCodeRole	M	"1" (Patient)
ntification)	ParticipantObjectDataLifeCycle	U	not specialized
	ParticipantObjectIDTypeCode	M	EV(2, RFC-3881, "Patient Number")
	ParticipantObjectSensitivity	U	not specialized
	PARTICIPANTOBJECTID	M	The subject ID in HL7 CX format.
	ParticipantObjectName	U	not specialized
	PARTICIPANTOBJECTQUERY	U	not specialized
	ParticipantObjectDetail	U	not specialized
prepopData	ParticipantObjectTypeCode	M	"2" (System)

ParticipantObjectTypeCodeRole	M	"20" (job)
ParticipantObjectDataLifeCycle	U	not specialized
ParticipantObjectIDTypeCode	M	EV2, RFC-3881, "Document ID")
ParticipantObjectSensitivity	U	not specialized
PARTICIPANTOBJECTID	M	The prepopData Document unique ID
ParticipantObjectName	U	not specialized
PARTICIPANTOBJECTQUERY	U	not specialized

5.Z3.2 Submit Form ([ITI-35]) audit messages

The Submit Form Transaction may be a PHI-Export event, as defined in ITI TF-2a: Table 3.20.6-1. The Actors involved in the transaction shall create audit data in conformance with DICOM (Supp 95) "Data Export"/"Data Import", with the following exceptions.

5.Z3.2.1 Form Filler audit message

	Field Name	Opt	Value Constraints		
Event	EventID	M	EV(110106, DCM, "Export")		
AuditMessage/ EventIdentification	EventActionCode	M	"R" (Read)		
Eventidentinodation	EventDateTime	M	not specialized		
	EventOutcomeIndicator	М	not specialized		
	EventTypeCode	M	EV("ITI-35", "IHE Transactions", "Submit Form")		
Source (Documer	Source (Document Source) (1)				
Human Requesto	r (0n)				
Destination (Doc	ument Repository) (1)				
Audit Source (Document Source) (1)					
Patient (1)					
FormData (1)	FormData (1)				

Where:

Source	UserID	M	Host system name
AuditMessage/ ActiveParticipant	AlternativeUserID	M	the process ID as used within the local operating system in the local system logs.
	UserName	U	not specialized
	UserIsRequestor	M	"true"
	RoleIDCode	M	EV(110153, DCM, "Source")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.
Human	UserID	M	Identity of the human that initiated the transaction.
Requestor	Alternative User ID	U	not specialized
(if known)	UserName	U	not specialized
AuditMessage/ ActiveParticipant	UserIsRequestor	M	"true"
	RoleIDCode	U	Access Control role(s) the user holds that allows this transaction.

NetworkAccessPointTypeCode	NA	
NetworkAccessPointID	NA	

460

Destination	UserID	M	SOAP endpoint URI.
AuditMessage/ ActiveParticipant	AlternativeUserID	U	not specialized
7 total or antio paint	UserName	U	not specialized
	UserIsRequestor	M	"false"
	RoleIDCode	M	EV(110152, DCM, "Destination")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.

Audit Source	AuditSourceID	U	Not specialized.
AuditMessage/ AuditSourceldentificati	AuditEnterpriseSiteID	U	not specialized
on	AuditSourceTypeCode	U	not specialized

Patient	ParticipantObjectTypeCode	M	"1" (Person)
(AuditMessage/ ParticipantObjectIde	ParticipantObjectTypeCodeRole	M	"1" (Patient)
ntification)	ParticipantObjectDataLifeCycle	U	not specialized
	ParticipantObjectIDTypeCode	M	EV(2, RFC-3881, "Patient Number")
	ParticipantObjectSensitivity	U	not specialized
	PARTICIPANTOBJECTID	M	The subject ID in HL7 CX format.
	ParticipantObjectName	U	not specialized
	<i>PARTICIPANTOBJECTQUERY</i>	U	not specialized
	ParticipantObjectDetail	U	not specialized
FormData	ParticipantObjectTypeCode	M	"2" (System)
(AuditMessage/ ParticipantObjectIde	ParticipantObjectTypeCodeRole	M	"20" (job)
ntification)	ParticipantObjectDataLifeCycle	U	not specialized
	ParticipantObjectIDTypeCode	M	EV(2, RFC-3881, "Form ID")
	ParticipantObjectSensitivity	U	not specialized
	PARTICIPANTOBJECTID	M	A form identifier
	ParticipantObjectName	U	not specialized
	PARTICIPANTOBJECTQUERY	U	not specialized
	ParticipantObjectDetail	U	not specialized

5.Z3.2.2 Form Receiver audit message

	Field Name	Opt	Value Constraints
Event	EventID	M	EV(110107, DCM, "Import")

	EventActionCode		"C" (Create)			
	EventDateTime		not specialized			
	EventOutcomeIndicator	M not specialized				
	EventTypeCode	M	EV("ITI-35", "IHE Transactions", "Submit Form")			
Source (Docume	nt Source) (1)					
Destination (Doc	ument Repository or Document Reci	pient) (1)				
Audit Source (Do	ocument Repository or Document Re	cipient) (1				
Patient (1)	Patient (1)					
FormData (1)						

Where:

Source	UserID	M	Host system name
AuditMessage/	AlternativeUserID	U	not specialized
ActiveParticipant	UserName	U	not specialized
	UserIsRequestor		"false"
	RoleIDCode	M	EV(110153, DCM, "Source")
	NetworkAccessPointTypeCode	M	"1" for machine (DNS) name, "2" for IP address
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.

Destination	UserID	M	SOAP endpoint URI				
AuditMessage/ ActiveParticipant	AlternativeUserID	M	the process ID as used within the local operating system in the local system logs.				
	UserName	U	not specialized				
	UserIsRequestor	M	"false"				
	RoleIDCode	M	EV(110152, DCM, "Destination")				
	NetworkAccessPointTypeCode		"1" for machine (DNS) name, "2" for IP address				
	NetworkAccessPointID	M	The machine name or IP address, as specified in RFC 3881.				

Audit Source	AuditSourceID	U	Not specialized.		
AuditMessage/ AuditSourceldentificati	AuditEnterpriseSiteID	U	not specialized		
on	AuditSourceTypeCode	U	not specialized		

Patient	ParticipantObjectTypeCode	M	"1" (Person)
(AuditMessage/ ParticipantObjectIde	ParticipantObjectTypeCodeRole	M	"1" (Patient)
ntification)	ParticipantObjectDataLifeCycle	U	not specialized
	ParticipantObjectIDTypeCode	M	EV(2, RFC-3881, "Patient Number")
	ParticipantObjectSensitivity	U	not specialized
	PARTICIPANTOBJECTID	M	The subject ID in HL7 CX format.
	ParticipantObjectName	U	not specialized
	PARTICIPANTOBJECTQUERY	U	not specialized
	ParticipantObjectDetail	U	not specialized
Form Data	ParticipantObjectTypeCode	M	"2" (System)

ParticipantObjectTypeCodeRole	M	"20" (job)
ParticipantObjectDataLifeCycle	U	not specialized
ParticipantObjectIDTypeCode	M	EV2, RFC-3881, "Form ID")
ParticipantObjectSensitivity	U	not specialized
PARTICIPANTOBJECTID	M	An identifier for the form
ParticipantObjectName	U	not specialized
PARTICIPANTOBJECTQUERY	U	not specialized
TAKITCHANTOBJECTQUERT		

5.Z3.3 Archive Form

The Archive Form Transaction may be a PHI-Export event, as defined in ITI TF-2a: Table 3.20.6-1. The Actors involved in the transaction shall create audit data in conformance with DICOM (Supp 95) "Data Export"/"Data Import", with the following exceptions.

5.Z3.3.1 Form Filler audit message

The requirements are the same as in section 5.Z3.2.1, Submit Form from Form Filler, except the eventType shall be EV("ITI-36", "IHE Transactions", "Archive Form").

475 **5.Z3.3.2 Form Archiver audit message**

The requirements are the same as in section 5.Z3.2.2, except the eventType shall be EV("ITI-36", "IHE Transactions", "Archive Form").

5.Z3.4 Retrieve Clarifications

There are no auditing requirements for this transaction as no PHI is exposed.

480

Namespace Additions

Add the following terms to the IHE Namespace:

Volume 3 – Content Modules

6 HL7 V3 CDA Content Modules

6.3.1 CDA Document Content Modules

490

Add to section 6.3.1

The prepop data is included in the Retrieve Form Request message sent by the RFD Form Filler to the RFD Form Manager during the Retrieve Form transaction.

Many tables will be introduced farther in this section. They contain a column titled "Optionality" which uses some code. Table 6.3.1-1 provides more information on this code.

Table 6.3.1-1: Optionality Key

Code	Value					
R	Required Section					
R2	Required Section if data present					
О	Optional section					

6.3.1.D1 Standards

500 CDAR2: Clinical Document Architecture, Release 2, 2005 HL7

CRS: Implementation Guide for CDA Release 2 – Level 1 and 2 – Care Record Summary (US realm), 2006, HL7.

CCD: ASTM/HL7 Continuity of Care Document (Draft)

ICH E2B M: ICH (International Conference on Harmonization) Harmonized Tripartite
505 Guideline: Data Elements for Transmission of Individual Case Safety Reports and its associated companion guide: Electronic Transmission of Individual Case Safety Reports Message Specification (ICH ICSR DTD Version 2.1)

6.3.1.D1.1 Data Element Index

A relevant data set for drug safety content reporting includes those elements identified within the US efforts under the Healthcare Information Technology Standards Panel (HITSP). The Drug Safety Content CCD described below overlays these data elements. This Data Element Index is an attempt to describe which sections are intended to cover which domains. The list includes data elements not currently represented in standards, most of which are optional. Where such standards do not exist, the Form Manager will enhance with non-standard fields.

6.3.1.D1.2 Form Data Element Mapping Specification

Table 6.3.1.D1.2-1: Form Data Element Mapping Specification

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Facility/ Importer Name	The name of the facility that the health care provider diagnosed the subject of the Case Report.	Facility		ClinicalDocument. author.assignedAu thor.representedOr ganization.Name			R
Facility Identifier	Unique facility identifier.	Facility		ClinicalDocument. author.assignedAu thor.representedOr ganization.Id			О
Address	The address (Street, City, State, Zip Code) of the person or facility that diagnosed the subject of the Case Report	Facility		ClinicalDocument. author.assignedAu thor.representedOr ganization.Addr			R
Telephone	The phone number of the person or facility that diagnosed the subject of the Case Report.	Facility		ClinicalDocument. author.assignedAu thor.representedOr ganization.Name telecom			О
Contact Person	The name of the person to be contacted for further information We assume this is the organizations contact	Facility		ClinicalDocument. author.assignedAu thor.representedOr ganization.associat edEntity[classCod e='CON'].assigned Person.name			О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Contact Phone Number	The telephone number for the contact person We assume this is the organizations contact	Facility		ClinicalDocument. author.assignedAu thor.representedOr ganization.associat edEntity[classCod e='CON'].assigned Person.telecom			О
Responsible physician/Hea lth care provider name	The name of the person that diagnosed the subject	Author		ClinicalDocument. author.assignedAu thor.assignedPerso n.name			О
User Facility / Importer Report Number	The number of the report assigned by the reporting facility	Author		ClinicalDocument. author.assignedAu thor.assignedPerso n.Id			О
Type of Report	The type of report (e.g., Drug Event Report, Healthcare Associated Infection Report, etc.)	TypeId					О
Report Date	The date that the Case Report is being sent	effectiveTime					О
Reported Previously	Indication if the information is supplemental to update in event already reported	versionNumber					О
Report sent to	The organization to which the report is submitted	informationRecipient		ClinicalDocument. informationRecipi ent.intendedRecipi ent.receivedOrgani zation			О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Report sent to FDA	Indication if the report is submitted to the Food and Drug Administration (FDA) – US	informationRecipient		ClinicalDocument. informationRecipi ent.intendedRecipi ent.receivedOrgani zation[id='FDA']			О
Date User Facility/Impor ter Became Aware of Event	The date the event was first recognized by an observer	Event	2.16.840.1.11 3883.10.20.1. 18	ClinicalDocument. component.structu redBody.compone nt.section.entry.ent ryRelationship.ob servation[templa teId.@root = 2.16.840.1.1138 83.10.20.1.18].ef fectiveTime.low. @value			О
Date report sent	The date the report is submitted	Not Known					О
Date sent to FDA	The date the report was submitted to the FDA – US	Not Known					О
Report Source	The originator of the report	Author		ClinicalDocument. author.assignedAu thor.representedOr ganization.Name			О
Reporter Name	The name of the person or facility sending the Case Report	Author		ClinicalDocument. Author.assignedA uthor.assignedPers on.name			R
Occupation of Reporter	The role of the reporter (e.g., physician, nurse,	no template					О

Rev. 1.2 – 2012-09-24

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
	administrator, etc.)						
Telephone	The phone number of the person or facility sending the Case Report	no template					О
Reporter Email	The email contact information for the reporter	no template					О
Type of Reporter	The role of the reporter with respect to the patient (e.g., treating or consulting clinician, case manager, etc.)	no template					О
Reporter Address (street name, city, state, zip code)	The address of the reporter	Author		ClinicalDocument. author.assignedAu thor.assignedPerso n.addr			О
Patient identifier	The identifier for the patient, may be a pseudonymized identifier	Patient		ClinicalDocument. recordTarget.patie ntRole.id			AE:R
Patient Name (first, MI, Last)	The name (preferably legal) of the subject of the case report.	Patient		ClinicalDocument. recordTarget.patie ntRole.patient.nam e			О
Date of Birth	Date of birth	Patient		ClinicalDocument. recordTarget.patie ntRole.patient.birt hTime			О
Age	The age of the subject	no template					0

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
	of the case report at time of diagnosis						
Gender	Patient sex	Patient		ClinicalDocument. recordTarget.patie ntRole.patient.adm inistrativeGenderC ode			О
Pregnancy Status	Whether the subject of the case report was pregnant at time of diagnosis.	no template					О
Estimated Deliver Date	Estimated date of delivery (or est. date of confinement [EDC])	Patient	EDD Observation 1.3.6.1.4.1.193 76.1.5.3.1.1.11. 2.3.1			EDD Observation 1.3.6.1.4.1.19376. 1.5.3.1.1.11.2.3.1	О
Weight	The weight of the patient at the time of the report	Patient	Vital Signs Observation 1.3.6.1.4.1.193 76.1.5.3.1.4.13.	ClinicalDocument. component.structu redBody.compone nt.section.entry.ent ryRelationship.ob servation[templa teId.@root = 1.3.6.1.4.1.19376. 1.5.3.1.4.13.2]. code.@displayNa me		Vital Signs Observation 1.3.6.1.4.1.19376. 1.5.3.1.4.13.2	О
Birth Weight	The weight of the patient at birth	Patient	Vital Signs Observation 1.3.6.1.4.1.193 76.1.5.3.1.4.13.	ClinicalDocument. component.structu redBody.compone nt.section.entry.ent ryRelationship.ob servation[templa			0

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
				teId.@root = 1.3.6.1.4.1.19376. 1.5.3.1.4.13.2]. code.@displayNa me			
Number of Siblings	The number of siblings in a multiple birth	Patient	Pregnancy Observation 1.3.6.1.4.1.193 76.1.5.3.1.4.13.				О
Patient Address (street name, city, state, zip code)	The address of the subject of the case report.	Patient		ClinicalDocument. recordTarget.patie ntRole.addr			О
Patient Telephone	The telephone of the subject of the case report.	Patient		ClinicalDocument. recordTarget.patie ntRole.telecom			О
Patient County	The county of the address of the subject of the case report	no template					0
Patient Country	The country of the address of the subject of the case report.	no template					О
Race	The race(s) of the subject of the case report.	Patient		ClinicalDocument. recordTarget.patie ntRole.patient.race Code			О
Ethnicity	The ethnicity of the subject of the case report	Patient		ClinicalDocument. recordTarget.patie ntRole.patient.ethn icGroupCode			О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Occupation	The occupation of subject of the case report. Enter as much detail as possible (e.g. Teacher in Pre-School facility)	no template					О
Date of Death	If patient has died, deceased date/time	no template					О
Date of Event	The date the event first occurred	no template					R
Description of Event	A textual description of the event	Event	originalText 1.3.6.1.4.1.193 76.1.5.3.1.3.13	#XX= ClinicalDocument. component.structu redBody.compone nt.section.entry[te mplateId/@root =1.3.6.1.4.1.19376 .1.5.3.1.3.13].entryRelationshi p.observation[te mplateId/@root = 2.16.840.1.1138 83.10.20.1.18].pa rticpant.participant role.playingEntity. code.originalText.r eference.@value //*[@ID='XX']		originalText 1.3.6.1.4.1.19376. 1.5.3.1.3.13 statusCode code='active'	О
Name of Condition	The name of the condition diagnosed	Event	displayName 1.3.6.1.4.1.193	ClinicalDocument. component.structu		displayName 1.3.6.1.4.1.19376.	R

Rev. 1.2 – 2012-09-24

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
	for the subject of the Case Report		76.1.5.3.1.3.13	redBody.compone nt.section.entry[te mplateId/@root =1.3.6.1.4.1.19376 .1.5.3.1.3.13].entryRelationshi p.observation[te mplateId/@root = 2.16.840.1.1138 83.10.20.1.18]. code.@displayNa me		1.5.3.1.3.13 statusCode code='active'	
Event Patient Problem Code	The locally determined code to identify the problem for subsequent follow up	no template					О
Event Device Problem Code	The locally determined code to identify the problem for subsequent follow up	no template					О
Type of Reportable Event	Seriousness of the event	no template					О
Type of Event and/or Issue		no template					О
Approximate Age of Device	The length of time the device has been in use for the patient	no template					О
Outcome	Textual description of	no template					0

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
attributed to AE	the outcome associated with the adverse event						
Patient Recovered Diagnosis	Final determination of reaction – diagnosis	no template					0
Location where Event Occurred	The location of the event – e.g., home, hospital, other facility, etc.	no template					0
Adverse Event Terms		no template					О
Event Abated after use stopped or dose reduced?	Indication that the event resolved / abated after usage stopped or dose reduced	no template					0
Event Reappeared after reintroduction	Indication if the reaction reoccurred after rechallenging the patient to the suspected substance	no template					О
Concomitant Medical Product Name	Other medical products in use for the patient to determine proximal relationships	Admission Medication				1.3.6.1.4.1.19376. 1.5.3.1.3.20	О
Therapy Dates	Dates of treatment with the suspected agent	no template					0
Pre-existing physician diagnosed	Allergies, conditions existing prior to the use of the suspected	no template					О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
allergies, birth defects. Medical conditions	agent						
Current Medications (Medwatch concomitant meds)	Other medications in use	Allergies and Other Adverse Reactions				1.3.6.1.4.1.19376. 1.5.3.1.3.13 statusCode code='active suspe nded aborted comp leted'	0
Previous Vaccine Type	The type of vaccine	no template					О
Previous Vaccine Manufacturer	The manufacturer of the vaccine dose	substanceAdministrati on/text/reference/@val ue				1.3.6.1.4.1.19376. 1.5.3.1.4.12	0
Previous Vaccine Lot #	The lot number of the vaccine dose	consumable/administer ableMaterial/ administerableMaterial / asMedicineManufactur er. manufacturer.id				1.3.6.1.4.1.19376. 1.5.3.1.4.12	О
Previous Vaccine Route/Site	The route of administration of the vaccine dose	Immunization				manufacturedLabe ledDrug 1.3.6.1.4.1.19376. 1.5.3.1.3.23	0
Vaccine # Previous Doses	The number of previous doses of the vaccine type	Immunization				lotNumberText 1.3.6.1.4.1.19376. 1.5.3.1.3.23	0
Previous Vaccine Date	The date the vaccination dose	Immunization				routeCode 1.3.6.1.4.1.19376.	О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Given	suspected was administered					1.5.3.1.3.23	
AE Following Prior Vaccination	Description of the adverse event	no template					О
Vaccine Purchased With	Indication of vaccination source (e.g., special program such as Vaccine for Children, state or provincial programs, etc.)	Immunization				effectiveTime 1.3.6.1.4.1.19376. 1.5.3.1.3.23	О
Suspect Product Name	Product name	no template					О
Product Dose	The dose of the product administered	no template					О
Product Frequency	The frequency with which the product was administered	Medications Administered				Product 1.3.6.1.4.1.19376. 1.5.3.1.3.21	О
Product Route Used	The route of administration of the product (e.g., oral, intravenous, intramuscular, etc.)	Medications Administered				Dose 1.3.6.1.4.1.19376. 1.5.3.1.3.21	О
Product Therapy Dates	Duration of therapy with the product	no template					О
Product Diagnosis for Use	The reason the product was initially used	Medications Administered				Route 1.3.6.1.4.1.19376. 1.5.3.1.3.21	О
Product Lot #	The product lot	no template					0

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
	number						
Expiration Date	The expiration date of the product	Medications Administered				Indication 1.3.6.1.4.1.19376. 1.5.3.1.3.21	О
NDC# or Unique ID	The unique identifier for the product	Medications Administered				Lot#	О
Event Abated after use stopped or dose reduced?	Indication that the event resolved / abated after usage stopped or dose reduced	Medications Administered				expirationTime	О
Event Reappeared after reintroduction ?	Indication if the reaction reoccurred after rechallenging the patient to the suspected substance	Medications Administered				Code 1.3.6.1.4.1.19376. 1.5.3.1.3.21	О
Suspect Medical Device Brand Name	Brand name of the suspect device	no template					О
Common Device Name	Common name of the device	no template					О
Manuf. name, City and State	Manufacturer of the device	no template					О
Medical Device Model #	Model number of the device	no template					О
Medical Device Catalog #	Catalog number of the device	no template					О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Medical Device Serial #	Serial number of the device	no template					0
Medical Device Lot #	Lot number of the device	no template					0
Medical Device Other #	Other identifiers for the device	no template					0
Operator of Device	The individual managing the device	no template					О
If implanted give date	Date of implantation of the device (if implanted)	no template					О
If explanted give date	Date device was removed (if removed)	no template					О
Is this a single use device that was reprocessed and reused on patient?	Indication if the device is a single-use device that was cleaned/reprocessed and is reused on the affected patient	no template					О
Name and Address of Reprocessor	Name and address of the individual / organization reprocessing the single use device	no template					О
Product available for evaluation?	Indication if the product is still available to be evaluated	no template					0
Date product returned to	If returned to the manufacturer, date of	no template					О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
manuf.	return						
Concomitant Medical Products & Therapy Dates	Other medical products and treatment used proximal to the event	no template					О
Signs and Symptoms	The signs and symptoms experienced by the patient	no template					О;
Symptom/ Illness Onset Date/Time	This is the range of time of which the problem was active for the patient; for PH: The date that the subject began having symptoms of condition being reported	Admission Medication				1.3.6.1.4.1.19376. 1.5.3.1.3.20	О
Patient Class	General type of patient, e.g., Inpatient, Outpatient, Emergency						0
Reporting Laboratory Identifier	Identifier for laboratory that is sending the result. This laboratory may be sending results received back from reference laboratories						О
Performing Laboratory	Laboratory that produced the test result. This may be a						0

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
	reference laboratory identifier.						
Report Date/Time	Date/time of report						О
Results Status	Status of report (preliminary, final, corrected)						О
Ordered Test Code	The identifier code for the requested observation/test/batter y						О
Resulted Test	"The identifier code for the specific test component resulted						О
Result Unit	Unit for numeric result context						О
Test Interpretation	Interpretation of test result, including the susceptibility test interpretation						О
Test Status	Status of the test result						С
Date of Test	The date that the laboratory test was performed for the subject of the Case Report.						О
Test Method	Testing method used to arrive at the specific result: The name of the laboratory test.						О

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Test Result	The test result of the laboratory test including any applicable result units of measure						О
Specimen Collection Date	The date that the specimen for the laboratory test was taken from the subject of the Case Report						О
Source of Specimen	The physical body location from where the specimen for the lab report was taken from the subject						О
Name of Organization Collecting Specimen	Name of organization collecting specimen which may be different from the organization performing the laboratory analysis						О
Diagnosis/Inju ry Code	Diagnosis or diagnoses assigned as a result of the encounter						О;
Diagnosis Type	Type of diagnosis being sent (admitting, working, final)						О;
Diagnosis Date/Time	The date that the subject of the Case Report was diagnosed with Condition above						О;

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
Previous Event Report Details	Definitions pending - see appendix for detail to be considered						О
Reason for Non- Evaluation	Definitions pending - see appendix for detail to be considered						О
Type of Follow-Up	Definitions pending - see appendix for detail to be considered						О
Type of Remedial Action	Definitions pending - see appendix for detail to be considered						О
Administratio n of Treatment	Was treatment administered?						R
Date of Admin of Treatment	The date treatment was administered. For HepB, Date HBV vaccine administered						R
Name of Treatment	Name of the treatment						R
Hospitalizatio n	If the subject of the case report was hospitalized						R
Admission Date	Enter the date that the subject of the Case Report was Admitted to the hospital.						О
Discharge Date	Enter the date that the subject of the Case Report was Discharged from the						R

Data Element	Definition	CCD Description	Template ID	CCD XPATH	Mapping Constraints(Co deSystem and /or value sets)	CCD Code	Optionality
	hospital						
Hospital Name	Name of hospital the case was admitted.						О
Recovered	Did the subject recover from the disease?						R
Death	Did the subject die as a result of the disease?						R

6.3.1.D1.3 Document Sample

6.3.1.D1.3.1 Immunizations Example

```
<component>
  <section>
    <templateId root='2.16.840.1.113883.10.20.1.6'/>
    <templateId root='1.3.6.1.4.1.19376.1.5.3.1.3.23'/>
    <id root=' ' extension=' '/>
    <code code='11369-6' displayName='HISTORY OF IMMUNIZATIONS'</pre>
      codeSystem='2.16.840.1.113883.6.1' codeSystemName='LOINC'/>
    <text>
     Text as described above
    </text>
    <entry>
      <!-- Required Immunization element -->
        <templateId root='1.3.6.1.4.1.19376.1.5.3.1.4.12'/>
    </entry>
  </section>
</component>
```

6.3.1.D1.3.2 Allergies and Other Adverse Reactions Examples

```
<component>
 <section>
    <templateId root='2.16.840.1.113883.10.20.1.2'/>
    <templateId root='1.3.6.1.4.1.19376.1.5.3.1.3.13'/>
    <id root=' ' extension=' '/>
    <code code='48765-2' displayName='Allergies, adverse reactions, alerts'</pre>
     codeSystem='2.16.840.1.113883.6.1' codeSystemName='LOINC'/>
    <text>
     Text as described above
   </text>
    <entry>
     <!-- Required Allergies and Intolerances Concern element -->
        <templateId root='1.3.6.1.4.1.19376.1.5.3.1.4.5.3'/>
    </entry>
  </section>
</component>
```

6.3.1.D1.3.3 Admission Medication History Example

```
<component>
     <section>
          <templateId root='1.3.6.1.4.1.19376.1.5.3.1.3.20'/>
```

6.3.1.D1.3.4 ClinicalDocument Header Example

```
<ClinicalDocument xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
                  xmlns="urn:hl7-org:v3"
xmnls:lab="urn:oid:1.3.6.1.4.1.19376.1.3.2"
                  xsi:schemaLocation="urn:hl7-org:v3 CDA.xsd">
 <realmCode code="US" codeSystem="2.16.1" codeSystemName="ISO3166-1"</pre>
displayName="US"/>
  <typeId extension="POCD HD000040" root="2.16.840.1.113883.1.3"/>
 <templateId extension="Lab.Report.Clinical.Document"</pre>
root="1.3.6.1.4.1.19376.1.3.3"/>
  <id root="1.19.6.11.13.103000012000025132.1181266627192.1"/>
  <code code="18725-2" codeSystem="2.16.840.1.113883.6.1"</pre>
codeSystemName="LOINC"
        displayName="Microbiology Studies"/>
 <title>Public Health Laboratory Report</title>
 <effectiveTime value="20070607183707.0222-0700"/>
  <confidentialityCode code="N" codeSystem="2.16.840.1.113883.5.25"</pre>
displayName="Normal"/>
  <languageCode code="en-US" codeSystem="2.16.840.1.113883.6.99"</pre>
codeSystemName="ISO639-1" displayName="en-US"/>
  <setId extension="07SR012345" root="2.16.840.1.113883.1.3"/>
<versionNumber value="1"/>
```

6.3.1.D1.3.5 Medications Administered Example

```
<component>
  <section>
    <templateId root='1.3.6.1.4.1.19376.1.5.3.1.3.21'/>
        <id root=' ' extension=' '/>
        <code code='18610-6' displayName='MEDICATION ADMINISTERED'
            codeSystem='2.16.840.1.113883.6.1' codeSystemName='LOINC'/>
        <text>
            Text as described above
```

6.3.1.D1.3.6 Author Example

```
<author>
 <time value="19990522"/>
 <assignedAuthor>
   <id extension="11111111" root="1.3.5.35.1.4436.7"/>
   <assignedPerson>
      <name>
       <prefix>Dr.</prefix>
       <given>Bernard</given>
       <family>Wiseman</family>
       <suffix>Sr.</suffix>
      </name>
    </assignedPerson>
    <representedOrganization>
       <id extension="aaaaabbbbb" root="1.3.5.35.1.4436.7"/>
       <name>Dr. Wiseman's Clinic</name>
    </representedOrganization>
 </assignedAuthor>
</author>
```

6.3.1.D1.3.7 Patient Example

6.3.1.D1.3.8 Vital Signs Observation Example

6.3.1.D1.3.9 Pregnancy Observation Example

</observation>

6.3.1.D1.3.10 EDD Observation Example

```
<observation classCode='OBS' moodCode='EVN'>
 <templateId root='1.3.6.1.4.1.19376.1.5.3.1.4.13'/>
<templateId root='1.3.6.1.4.1.19376.1.5.3.1.1.11.2.3.1'>
<statusCode code='completed'/>
<effectiveTime value=' '/>
<author typeCode='AUT'>
  <time value=' '/>
  <assignedAuthor>
    <id root=' ' extension=' '/>
  </assignedAuthor>
 </author>
 <id root=' ' extension=' '/>
<code code='11778-8'</pre>
      displayName='DELIVERY DATE-TMSTP-PT-^PATIENT-QN-CLINICAL.ESTIMATED'
      codeSystem='2.16.840.1.113883.6.1' codeSystemName='LOINC'/>
 <text><reference value='id-foo'/></text>
 <value xsi:type='TS' value=' '/>
<entryRelationship typeCode='SPRT'>
  <observation classCode='OBS' moodCode='EVN'>
    <id root=' ' extension=' '/>
    <statusCode code='completed'/>
    <effectiveTime value=' '/>
     <author typeCode='AUT'>
       <time value=' '/>
        <assignedAuthor classCode=' '>
          <id root=' ' extension=' '/>
        </assignedAuthor>
     </author>
     <code code='[11779-6|(xx-EDD-by-PE)|11781-2|(xx-EDD-by-Qck)|(xx-EDD-by-</pre>
Fund) ] '
           codeSystem='2.16.840.1.113883.6.1' codeSystemName='LOINC'/>
    <value type='TS' value=' '>
    <entryRelationship typeCode='DRIV'>
       <observation classCode='OBS' moodCode='EVN'>
         <id root=' ' extension=' '/>
         <statusCode code='completed'/>
         <effectiveTime value=' '/>
         <author typeCode='AUT'>
          <time value=' '/>
           <assignedAuthor>
             <id root=' ' extension=' '/>
           </assignedAuthor>
         </author>
         <informant typeCode='INF'>
           <relatedEntity classCode=' '>
             <id root=' ' extension=' '/>
           </relatedEntity>
```

IHE Quality, Research and Public Health Technical Framework Supplement – Drug Safety Content (DSC)

Appendices

Appendix A: Reference Implementation

Drug Safety Content CCD to E2B Crosswalk

This section is intended to be a guide as to how a Form Manager would crosswalk an individual case safety report CCD structure into a standard used for routine reporting by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMEA), the Ministry of Health Labour and Welfare (MHLW) in Japan and HealthCanada. Some harmonization work has been done by HL7, ISO and CEN and ICH to align reporting data elements within the E2B standard, moving from the existing E2B M to E2B R3. The harmonization work also modifies the messaging requirements as the Individual Case Safety Report (ICSR) R3.

The E2B R3 content standard has been finalized and is now published for public comments. In the interim, regulatory bodies will continue to receive electronic submissions from pharmaceutical companies using E2B M transmission standards. The benefit for EHR implementations and EHR vendors is alignment of all reporting to external agencies by use of CDA mapping and RFD infrastructure.

The expected mid-term goal is for the Form Manager to map to ICSR R3 and the related content, E2B R3. This reference implementation constrains the data element list to only those elements with E2B M tags (appendix A.1) and E2B R3 tags (appendix A.2). Some data elements are not represented within E2B M and E2B R3, even though there may be CCD elements that can capture them.

The adopted format for this transformation from one structure to the other is an XSLT. The intent is to have this XSLT not be presented here within the DSC profile and remain static, but to further develop and refine this XSLT as supplemental material. The goal is to allow additional Use Cases to drive different flavors of transformations all of which might be available to be referenced. IHE is developing processes which aren't ready at time of this publication to help maintain source control and facilitate sharing and updating of this as well as other reference transformations. When the IHE process and procedures are determined this section will refer to those documents.

The list includes data elements not currently represented in standards, most of which are optional. Where such standards do not exist, the Form Manager will enhance with non-standard fields.

It should be noted that CDISC is currently working on a mapping between CDASH and E2B M. The mapping isn't ready at the time of this publication, but this latter will be updated to include those mappings once the mapping is available.

IHE Quality, Research and Public Health Technical Framework Supplement – Drug Safety Content (DSC)

For more information on the E2B R3 standard and the mapping between E2B R3 and E2B M, click on the following link: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm274966.h tm

A.1 Drug Safety Content CCD to E2B M Crosswalk

53

		Drug Safe	ety Content CCD to E	2B M Cross	walk	
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code
Facility/ Importer Name	The name of the facility that the health care provider diagnosed the subject of the Case Report.	R	reporterorganization	A.2.1.2a	Facility	Author.assignedAuthor.represen tedOrganization.Name
Facility Identifier	Unique facility identifier.	0			Facility	Author.assignedAuthor.represen tedOrganization.Id
Address	The address (Street, City, State, Zip Code) of the person or facility that diagnosed the subject of the Case Report	R	reporteraddress, reporterstreet,reportercity,rep orterpostalcode,reporterstate	A.2.1.2c, A.2.1.2d, A.2.1.2e, A.2.1.2f	Facility	Author.assignedAuthor.represen tedOrganization.Addr
Telephone	The phone number of the person or facility that diagnosed the subject of the Case Report.	О			Facility	Author.assignedAuthor.represen tedOrganization.Name telecom
Contact Person	The name of the person to be contacted for further information	О	sendergivename, senderfamilyname	A.3.1.3c, A.3.1.3e		
Contact Phone Number	The telephone number for the contact person	0	sendertel	A.3.1.4f		

		Drug Safe	ety Content CCD to E	E2B M Cross	walk	
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code
Responsible physician/Health care provider name	The name of the person that diagnosed the subject	О	reportergivename, reporterfamilyname	A.2.1.1b, A.2.1.1d	Author	Author.assignedAuthor.assigned Person.name
User Facility / Importer Report Number	The number of the report assigned by the reporting facility	О	patienthospitalrecordnumb	B.1.1.1c	Author	Author.assignedAuthor.assigned Person.Id
Type of Report	The type of report (e.g., Drug Event Report, Healthcare Associated Infection Report, etc.)	О			no template (data element required)	
Report Date	The date that the Case Report is being sent	0	transmissiondateformat, transmissiondate	A.1.3a, A.1.3b	no template	
Reported Previously	Indication if the information is supplemental to update in event already reported	О			no template	
Report sent to	The organization to which the report is submitted	0	receiver	A.3.2	no template	
Report sent to FDA	Indication if the report is submitted to the Food and Drug Administration (FDA) – US	О			no template	

		Drug Safe	ety Content CCD to E	2B M Cross	walk	
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code
Date User Facility/Importer Became Aware of Event	The date the event was first recognized by an observer	0	receivedate	A.1.6b		observation[templateId/@ro ot = 2.16.840.1.113883.10.20.1.1 8]/effectiveTime/low/@value
Date report sent	The date the report is submitted	О	transmissiondateformat, transmissiondate	A.1.3a, A.1.3b	no template	
Date sent to FDA	The date the report was submitted to the FDA – US	О			no template	
Report Source	The originator of the report	О	?		no template	
Reporter Name	The name of the person or facility sending the Case Report	R	sendergivename, senderfamilyname	A.3.1.3c, A.3.1.3e	no template	
Occupation of Reporter	The role of the reporter (e.g., physician, nurse, administrator, etc.)	0			no template	
Telephone	The phone number of the person or facility sending the Case Report	0			no template	
Reporter Email	The email contact information for the reporter	О			no template	

Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code	
Type of Reporter	The role of the reporter with respect to the patient (e.g., treating or consulting clinician, case manager, etc.)	0	qualification	A.2.1.4	no template		
Reporter Address (street name, city, state, zip code)	The address of the reporter	0	reporteraddress, reporterstreet,reportercity,rep orterpostalcode,reporterstate	A.2.1.2c, A.2.1.2d, A.2.1.2e, A.2.1.2f	Author	Author.assignedAuthor.assigned Person.addr	
Patient identifier	The identifier for the patient, may be a pseudonymized identifier	AE:R	patientinital, patientgpmedicalrecordnumb	B.1.1, B.1.1.1a	Patient	ClinicalDocument.recordTarget. patientRole.id	
Patient Name (first, MI, Last)	The name (preferably legal) of the subject of the case report.	0			Patient	ClinicalDocument.recordTarget. patientRole.patient.name	
Date of Birth	Date of birth	О	patientbirthdateformat, patientbirthdate	B.1.2.1a, B.1.2.1b	Patient	ClinicalDocument.recordTarget. patientRole.patient.birthTime	
Age	The age of the subject of the case report at time of diagnosis	0	patientonsetage	B.1.2.2a	no template		
Gender	Patient sex	О	patientsex	B.1.5	Patient	ClinicalDocument.recordTarget. patientRole.patient.administrati veGenderCode	

Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code	
Pregnancy Status	Whether the subject of the case report was pregnant at time of diagnosis.	О			no template		
Estimated Deliver Date	Estimated date of delivery (or est. date of confinement [EDC])	0			Patient	EDD Observation 1.3.6.1.4.1.19376.1.5.3.1.1.11.2. 3.1	
Weight	The weight of the patient at the time of the report	О	patientweight	B.1.3	Patient	Vital Signs Observation 1.3.6.1.4.1.19376.1.5.3.1.4.13.2 code/@code = 3141-9	
Birth Weight	The weight of the patient at birth	О			Patient	Vital Signs Observation 1.3.6.1.4.1.19376.1.5.3.1.4.13.2	
Number of Siblings	The number of siblings in a multiple birth	O			Patient	Pregnancy Observation 1.3.6.1.4.1.19376.1.5.3.1.4.13.5	
Patient Address (street name, city, state, zip code)	The address of the subject of the case report.	О			Patient	ClinicalDocument.recordTarget. patientRole.addr	
Patient Telephone	The telephone of the subject of the case report.	О			Patient	ClinicalDocument.recordTarget. patientRole.telecom	

Drug Safety Content CCD to E2B M Crosswalk Option-**Data Element Definition E2B M Description** E2B M Code **CCD Description CCD Code** ality The county of the address of the Patient County O no template subject of the case report The country of the address of the O Patient Country no template subject of the case report. The race(s) of the ClinicalDocument.recordTarget. subject of the case Patient Race O patientRole.patient.raceCode report. The ethnicity of the ClinicalDocument.recordTarget. O Ethnicity subject of the case Patient patientRole.patient.ethnicGroup Code report The occupation of subject of the case report. Enter as Occupation much detail as O no template possible (e.g. Teacher in Pre-School facility) If patient has died, patientdeathdateformat, B.1.9.1a, Date of Death O no template deceased date/time patientdeathdate B.1.9.1b

Drug Safety Content CCD to E2B M Crosswalk Option-**Data Element Definition E2B M Description** E2B M Code **CCD Description CCD Code** ality The date the event Date of Event R no template first occurred #XX =observation[templateId/@ro 2.16.840.1.113883.10.20.1.1 A textual description reactionstartdateformat, B.2.i.4a, Description of Event Event 8]/particpant/participantrole/pla of the event reactionstartdate B.2.i.4b yingEntity/code/originalText/ref erence/@value //*[@ID='XX'] observation[templateId/@ro ot =The name of the condition diagnosed 2.16.840.1.113883.10.20.1.1 Name of Condition R primarysourcereaction B.2.i.0 Event for the subject of the 8]/particpant/participantrole/pla Case Report yingEntity/code/@displayName The locally determined code to **Event Patient Problem** identify the problem O reactionmeddrallt B.2.i.1b no template Code for subsequent follow up

	Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code		
Event Device Problem Code	The locally determined code to identify the problem for subsequent follow up	0			no template			
Type of Reportable Event	Seriousness of the event	0			no template			
Type of Event and/or Issue		0			no template			
Approximate Age of Device	The length of time the device has been in use for the patient	0			no template			
Outcome attributed to AE	Textual description of the outcome associated with the adverse event	0	reactionoutcome	B.2.i.8	no template			
Patient Recovered Diagnosis	Final determination of reaction – diagnosis	О	reactionoutcome	B.2.i.8	no template			

	Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code		
Location where Event Occurred	The location of the event – e.g., home, hospital, other facility, etc.	О			no template			
Adverse Event Terms		О	reactionmeddrallt	B.2.i.1b	no template			
Event Abated after use stopped or dose reduced?	Indication that the event resolved / abated after usage stopped or dose reduced	О	drugrecurreadministration	B.4.k.17.1	no template			
Event Reappeared after reintroduction	Indication if the reaction reoccurred after rechallenging the patient to the suspected substance	0	drugrecurreadministration	B.4.k.17.1	no template			
Concomitant Medical Product Name	Other medical products in use for the patient to determine proximal relationships	О	medicinalproduct, drugcharacterization	B.4.k.2.1, B.4.k.1	Admission Medication	1.3.6.1.4.1.19376.1.5.3.1.3.20		
Therapy Dates	Dates of treatment with the suspected agent	О			no template			

	Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code		
Pre-existing physician diagnosed allergies, birth defects. Medical conditions	Allergies, conditions existing prior to the use of the suspected agent	0	drugstartdateformat, drugstartdate, drugendateformat, drugendate	B.4.k.12a, B.4.k.12b, B.4.k.14a, B.4.k.14b	no template			
Current Medications (Medwatch concomitant meds)	Other medications in use		patientepisodename	B.1.7.1a.2 ?	Allergies and Other Adverse Reactions	1.3.6.1.4.1.19376.1.5.3.1.3.13 statusCode code='active suspended aborted completed'		
Previous Vaccine Type	The type of vaccine	0	medicinalproduct, drugeharacterization	B.4.k.2.1, B.4.k.1?	no template			
Previous Vaccine Manufacturer	The manufacturer of the vaccine dose	0			substanceAdministrati on/consumable/manuf acturedOrganization/n ame	1.3.6.1.4.1.19376.1.5.3.1.4.12		
Previous Vaccine Lot #	The lot number of the vaccine dose	0			consumable/manufact uredProduct/manufact uredMaterial/lotNumb erText asMedicineManufactu rer. manufacturer.id	1.3.6.1.4.1.19376.1.5.3.1.4.12		

Drug Safety Content CCD to E2B M Crosswalk Option-**Data Element Definition E2B M Description** E2B M Code **CCD Description CCD Code** ality routeCode The route of Previous Vaccine 1.3.6.1.4.1.19376.1.5.3.1.3.23 administration of the O Immunization Route/Site approachsiteCode/originalText/r vaccine dose eference/@value The number of Vaccine # Previous previous doses of the Immunization Doses vaccine type The date the vaccination dose Previous Vaccine Date O Immunization Given suspected was administered **AE Following Prior** Description of the O no template Vaccination adverse event Indication of vaccination source (e.g., special program such as Vaccine Purchased effectiveTime O Immunization Vaccine for With 1.3.6.1.4.1.19376.1.5.3.1.3.23 Children, state or provincial programs, etc.) Product Suspect Product Name Product name O no template 1.3.6.1.4.1.19376.1.5.3.1.3.19

Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code	
Product Dose	The dose of the product administered	0			no template	Dose 1.3.6.1.4.1.19376.1.5.3.1.3.19	
Product Frequency	The frequency with which the product was administered	0	medicinalproduct, drugcharacterization	B.4.k.2.1, B.4.k.1	Medications Administered		
Product Route Used	The route of administration of the product (e.g., oral, intravenous, intramuscular, etc.)	O	drugdosagetext	B.4.k.6	Medications Administered		
Product Therapy Dates	Duration of therapy with the product	0	drugseparatedosagenumb	B.4.k.5.3	no template		
Product Diagnosis for Use	The reason the product was initially used	0	drugadministrationroute	B.4.k.8	Medications Administered	Route 1.3.6.1.4.1.19376.1.5.3.1.3.21	

	Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code		
Product Lot #	The product lot number	0	drugstartdateformat, drugstartdate, drugendateformat, drugendate	B.4.k.12a, B.4.k.12b, B.4.k.14a, B.4.k.14b	no template			
Expiration Date	The expiration date of the product	0	drugindication	B.4.k.11b	Medications Administered	Indication 1.3.6.1.4.1.19376.1.5.3.1.3.21		
NDC# or Unique ID	The unique identifier for the product	0	drugbatchnumb	B.4.k.3	Medications Administered	Lot#		
Event Abated after use stopped or dose reduced?	Indication that the event resolved / abated after usage stopped or dose reduced	0			Medications Administered	expirationTime		
Event Reappeared after reintroduction?	Indication if the reaction reoccurred after rechallenging the patient to the suspected substance	0	drugauthorizationumb	B.4.k.4.1	Medications Administered	Code 1.3.6.1.4.1.19376.1.5.3.1.3.21		

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition E2B M Description CCD Description CCD Code Data Element** E2B M Code ality Brand name of the Suspect Medical O drugrecurreadministration B.4.k.17.1 no template Device Brand Name suspect device Common name of Common Device O drugrecurreadministration no template B.4.k.17.1 Name the device Manuf. name, City and Manufacturer of the O no template device State Medical Device Model Model number of the O no template device Catalog number of the device Medical Device O no template Catalog #

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition E2B M Description CCD Description CCD Code Data Element** E2B M Code ality Medical Device Serial Serial number of the no template device Lot number of the Medical Device Lot# O no template device Medical Device Other Other identifiers for O no template the device The individual Operator of Device no template managing the device Date of implantation If implanted give date of the device (if O no template implanted)

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition Data Element E2B M Description** E2B M Code **CCD Description CCD Code** ality Date device was If explanted give date removed (if O no template removed) Indication if the Is this a single use device is a single-use device that was device that was no template cleaned/reprocessed reprocessed and reused on patient? and is reused on the affected patient Name and address of the individual / Name and Address of O organization no template Reprocessor reprocessing the single use device Indication if the Product available for product is still O no template evaluation? available to be evaluated If returned to the Date product returned no template manufacturer, date of O to manuf. return

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition Data Element E2B M Description** E2B M Code **CCD Description CCD Code** ality Other medical Concomitant Medical products and Products & Therapy O no template treatment used Dates proximal to the event The signs and symptoms Signs and Symptoms no template O; experienced by the patient This is the range of time of which the problem was active for the patient; for Symptom/ Illness Admission PH: The date that the O 1.3.6.1.4.1.19376.1.5.3.1.3.20 Onset Date/Time Medication subject began having symptoms of condition being reported General type of patient, e.g., Patient Class O Inpatient, Outpatient, Emergency

	Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code		
Reporting Laboratory Identifier	Identifier for laboratory that is sending the result. This laboratory may be sending results received back from reference laboratories	О	reactionstartdateformat, reactionstartdate	B.2.i.4a, B.2.i.4b				
Performing Laboratory	Laboratory that produced the test result. This may be a reference laboratory identifier.	О						
Report Date/Time	Date/time of report	О						

Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code	
Results Status	Status of report (preliminary, final, corrected)	О					
Ordered Test Code	The identifier code for the requested observation/test/batte ry	0					
Resulted Test	"The identifier code for the specific test component resulted	О					
Result Unit	Unit for numeric result context	0					
Test Interpretation	Interpretation of test result, including the susceptibility test interpretation	О					
Test Status	Status of the test result	С					

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition Data Element E2B M Description** E2B M Code **CCD Description CCD Code** ality The date that the laboratory test was Date of Test performed for the subject of the Case Report. Testing method used to arrive at the Test Method specific result :The O name of the laboratory test. The test result of the laboratory test Test Result including any O testdateformat, testdate B.3.1a, B.3.1b applicable result units of measure The date that the specimen for the laboratory test was Specimen Collection taken from the Date subject of the Case Report

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition Data Element E2B M Description** E2B M Code **CCD Description CCD Code** ality The physical body location from where Source of Specimen the specimen for the B.3.1d testresult lab report was taken from the subject Name of organization collecting specimen Name of Organization which may be O Collecting Specimen different from the organization performing the laboratory analysis Diagnosis or diagnoses assigned Diagnosis/Injury Code O; as a result of the encounter

	Drug Safety Content CCD to E2B M Crosswalk								
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code			
Diagnosis Type	Type of diagnosis being sent (admitting, working, final)	О;							
Diagnosis Date/Time	The date that the subject of the Case Report was diagnosed with Condition above	О;							
Previous Event Report Details	Definitions pending - see appendix for detail to be considered	О							
Reason for Non- Evaluation	Definitions pending - see appendix for detail to be considered	О							

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition E2B M Description Data Element** E2B M Code **CCD Description CCD Code** ality Definitions pending see appendix for Type of Follow-Up O detail to be considered Definitions pending see appendix for Type of Remedial O detail to be Action considered Was treatment Administration of R administered? Treatment The date treatment was administered. Date of Admin of For HepB, Date R Treatment HBV vaccine administered Name of the R Name of Treatment treatment If the subject of the Hospitalization case report was R hospitalized

Drug Safety Content CCD to E2B M Crosswalk Option-**Definition Data Element E2B M Description** E2B M Code **CCD Description CCD Code** ality Enter the date that the subject of the Case Report was O Admission Date Admitted to the hospital. Enter the date that the subject of the Discharge Date Case Report was R Discharged from the hospital Name of hospital the Hospital Name case was admitted. Did the subject recover from the Recovered R disease? Did the subject die Death as a result of the R disease? Data Element Definition O reactionoutcome B.2.i.8

Drug Safety Content CCD to E2B M Crosswalk							
Data Element	Definition	Option- ality	E2B M Description	E2B M Code	CCD Description	CCD Code	
Facility/ Importer Name	The name of the facility that the health care provider diagnosed the subject of the Case Report.	0	seriousnessdeath	A.1.5.2a			

78

A.2 Drug Safety Content CCD to E2B R3 Crosswalk

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code Data Element** ality The name of the facility that the reporterorganization Facility/ Importer Author.assignedAuthor.represen A.2.r.1.2a health care provider diagnosed R Facility tedOrganization.Name Name the subject of the Case Report. Author.assignedAuthor.represen O Facility Identifier Unique facility identifier. Facility tedOrganization.Id A.2.r.1.2c Reporter's street The address (Street, City, State, A.2.r.1.2d Zip Code) of the person or Reporter's city Author.assignedAuthor.represen Address R 4.2.r.1.2e Facility facility that diagnosed the Reporter's state or province tedOrganization.Addr A.2.r.1.2f subject of the Case Report Reporter's postcode The phone number of the person Author.assignedAuthor.represen or facility that diagnosed the Telephone O Facility A.2.r.1.2g tedOrganization.Name telecom subject of the Case Report. sendergivename, senderfamilyname A.3.3c The name of the person to be A.3.3e contacted for further Contact Person O information

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code Data Element** ality The telephone number for the sendertel O Contact Phone Number A.3.4f contact person. reportergivename, A.2.r.1.1b Responsible reporterfamilyname The name of the person that Author.assignedAuthor.assigned A.2.r.1.1d physician/Health care O Author diagnosed the subject Person.name provider name The number of the report B.1.1.1c Patienthospitalrecordnumb User Facility / Importer Author.assignedAuthor.assigned assigned by the reporting O Author Report Number Person.Id facility The type of report (e.g., Drug Event Report, Healthcare Type of Report R Type of Report A.1.4 no template Associated Infection Report, etc.) The date that the Case Report is transmissiondateformat, o dateformat (Ignore being sent transmissiondate field) Report Date no template R A.1.3 Indication if the information is O Date of Most Recent Reported Previously supplemental to update in event A.1.6 no template R Information for this report already reported

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Data Element Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code** ality O The organization to which the Receiver no template Report sent to report is submitted Indication if the report is submitted to the Food and Drug O Report sent to FDA no template Administration (FDA) – US Date User effectiveTime The date the event was first Facility/Importer 1.3.6.1.4.1.19376.1.5.3.1.3.13 O receivedate A.1.6b Event Became Aware of recognized by an observer statusCode code='active' Event dateformat (Ignore transmissiondateformat, Date report sent The date the report is submitted O field) no template transmissiondate , A.1.3b

no template

no template

no template

sendergivename,

senderfamilyname

O

O

R

O

The date the report was

submitted to the FDA – US

The originator of the report

The name of the person or

facility sending the Case Report

A.3.3c

A.3.3e

Date sent to FDA

Report Source

Reporter Name

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Data Element Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code** ality The role of the reporter (e.g., Occupation of physician, nurse, administrator, О no template Reporter etc.) The phone number of the person sendertelephone or facility sending the Case O Telephone no template A.3.4f Report The email contact information Reporter Email O no template senderemail A.3.4l for the reporter The role of the reporter with qualification respect to the patient (e.g., O Type of Reporter A.2.r.1.4 no template treating or consulting clinician, case manager, etc.) reporteraddress, reporterstreet, reportercity, r 4.2.r.1.2c eporterpostalcode, reporters Reporter Address 4.2.r.1.2d Author.assignedAuthor.assigned tate O (street name, city, state, The address of the reporter Author A.2.r.1.2e Person.addr zip code) A.2.r.1.2f patientinital, The identifier for the patient, patientgpmedicalrecordnu ClinicalDocument.recordTarget. Patient identifier may be a pseudonymized AE:R B.1.1, B.1.1.1a Patient patientRole.id identifier

Rev. 1.2 – 2012-09-24

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Data Element Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code** ality O Patient Name (first, MI, The name (preferably legal) of ClinicalDocument.recordTarget. patient B.1.1 Patient patientRole.patient.name the subject of the case report. Last) R O patientbirthdateformat, dateformat (Ignore field) ClinicalDocument.recordTarget. patientbirthdate Date of Birth Date of birth Patient patientRole.patient.birthTime B.1.2.1 O but required patientonsetage The age of the subject of the B.1.2.2a Age no template case report at time of diagnosis B1.2.2b is populat ed ClinicalDocument.recordTarget. O patientsex patientRole.patient.administrati Gender Patient sex B.1.5 Patient R veGenderCode Whether the subject of the case Pregnancy Status report was pregnant at time of O no template diagnosis. EDD Observation Estimated date of delivery (or Estimated Deliver Date O Patient 1.3.6.1.4.1.19376.1.5.3.1.1.11.2. est. date of confinement [EDC]) 3.1

Rev. 1.2 – 2012-09-24

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Definition E2B R3 Description CCD Description CCD Code Data Element** E2B R3 Code ality The weight of the patient at the Vital Signs Observation Weight O patientweight B.1.3 Patient 1.3.6.1.4.1.19376.1.5.3.1.4.13.2 time of the report The weight of the patient at Vital Signs Observation Birth Weight O Patient birth 1.3.6.1.4.1.19376.1.5.3.1.4.13.2 The number of siblings in a Pregnancy Observation Number of Siblings \mathbf{O} Patient 1.3.6.1.4.1.19376.1.5.3.1.4.13.5 multiple birth Patient Address (street The address of the subject of the ClinicalDocument.recordTarget. name, city, state, zip Patient case report. patientRole.addr code) The telephone of the subject of ClinicalDocument.recordTarget. O Patient Telephone Patient the case report. patientRole.telecom The county of the address of the Patient County no template subject of the case report ClinicalDocument.recordTarget. The race(s) of the subject of the O Patient Race case report. patientRole.patient.raceCode ClinicalDocument.recordTarget. The ethnicity of the subject of O Ethnicity patientRole.patient.ethnicGroup Patient the case report Code

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Occupation	The occupation of subject of the case report. Enter as much detail as possible (e.g. Teacher in Pre-School facility)	О			no template				
Date of Death	If patient has died, deceased date/time	0	patientdeathdateformat, patientdeathdate	dateformat (Ignore field) B.1.9.1	no template				
Date of Event	The date the event first occurred	R			no template				
Description of Event	A textual description of the event	0	reactionstartdateformat, reactionstartdate reactionstartdate	Date format, B.2.i.3	Event	originalText 1.3.6.1.4.1.19376.1.5.3.1.3.13 statusCode code='active'			
Name of Condition	The name of the condition diagnosed for the subject of the Case Report	R	primarysourcereaction	B.2.i.0.a1	Event	displayName 1.3.6.1.4.1.19376.1.5.3.1.3.13 statusCode code='active'			

86

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Event Patient Problem Code	The locally determined code to identify the problem for subsequent follow up	О	reactionmeddrallt	B.2.i.1b	no template				
Event Device Problem Code	The locally determined code to identify the problem for subsequent follow up	О			no template				
Type of Reportable Event	Seriousness of the event	0			no template				
Type of Event and/or Issue		0			no template				
Approximate Age of Device	The length of time the device has been in use for the patient	0			no template				

Drug Safety Content CCD to E2B R3 Crosswalk Option-**E2B R3 Description Data Element Definition** E2B R3 Code **CCD Description CCD Code** ality Textual description of the Outcome attributed to reactionoutcome outcome associated with the R no template AE B.2.i.6 adverse event reactionoutcome Patient Recovered Final determination of reaction O no template Diagnosis - diagnosis B.2.i.6 The location of the event -e.g., Location where Event O home, hospital, other facility, no template Occurred etc. Reactionmeddrallt Adverse Event Terms B.2.i.1b no template drugrecurreadministration Event Abated after use Indication that the event no field stopped or dose resolved / abated after usage О no template reduced? stopped or dose reduced Indication if the reaction drugrecurreadministration Event Reappeared after reoccurred after rechallenging no field O no template reintroduction the patient to the suspected substance

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Data Element Definition E2B R3 Description CCD Description CCD Code** E2B R3 Code ality medicinalproduct, B.4.k.2.2, B.4.k.1 Other medical products in use drugcharacterization Concomitant Medical Admission for the patient to determine O 1.3.6.1.4.1.19376.1.5.3.1.3.20 Medication Product Name proximal relationships Dates of treatment with the O Therapy Dates no template suspected agent drugstartdateformat, drugstartdate, Date format Pre-existing physician drugendateformat, B.4.k.4.r.6 Allergies, conditions existing diagnosed allergies, drugendate Date format prior to the use of the suspected O no template birth defects. Medical B.4.k.4.r.7 agent conditions O but 1.3.6.1.4.1.19376.1.5.3.1.3.13 **Current Medications** required Patientepisodename Allergies and Other B.1.7.1.r.a.2 (Medwatch Other medications in use statusCode Adverse Reactions concomitant meds) code='active|suspended|aborted| B.1.7.1.r. completed' a.1 is populated medicinalproduct, B.4.k.2.2 Previous Vaccine Type The type of vaccine O no template drugcharacterization B.4.k.1

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Data Element Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code** ality substanceAdministrati The manufacturer of the vaccine Previous Vaccine on/text/reference/@va 1.3.6.1.4.1.19376.1.5.3.1.4.12 Manufacturer dose lue consumable/administe rableMaterial/ Previous Vaccine Lot The lot number of the vaccine administerableMateria 1.3.6.1.4.1.19376.1.5.3.1.4.12 dose asMedicineManufactu rer. manufacturer.id The route of administration of manufacturedLabeledDrug Previous Vaccine O Immunization 1.3.6.1.4.1.19376.1.5.3.1.3.23 Route/Site the vaccine dose Vaccine # Previous The number of previous doses lotNumberText O Immunization of the vaccine type 1.3.6.1.4.1.19376.1.5.3.1.3.23 Doses Previous Vaccine Date The date the vaccination dose routeCode O Immunization 1.3.6.1.4.1.19376.1.5.3.1.3.23 Given suspected was administered **AE Following Prior** Description of the adverse event O no template Vaccination

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Vaccine Purchased With	Indication of vaccination source (e.g., special program such as Vaccine for Children, state or provincial programs, etc.)	0			Immunization	effectiveTime 1.3.6.1.4.1.19376.1.5.3.1.3.23			
Suspect Product Name	Product name	О			no template				
Product Dose	The dose of the product administered	0			no template				
Product Frequency	The frequency with which the product was administered	0		B.4.k.2.2 B.4.k.1	Medications Administered	Product 1.3.6.1.4.1.19376.1.5.3.1.3.21			
Product Route Used	The route of administration of the product (e.g., oral, intravenous, intramuscular, etc.)	0	drugdosagetext	B.4.k.4.r.10	Medications Administered	Dose 1.3.6.1.4.1.19376.1.5.3.1.3.21			

Drug Safety Content CCD to E2B R3 Crosswalk Option-**CCD Description Data Element Definition E2B R3 Description** E2B R3 Code **CCD Code** ality No field: If set, use as Product Therapy Duration of therapy with the O drugseparatedosagenumb no template multiplication factor of Dates product dose number: dose(R3) = dose(R2) *number of separate dosages The reason the product was Product Diagnosis for Medications Route B.4.k.4.r.12.1 O drugadministrationroute initially used Use Administered 1.3.6.1.4.1.19376.1.5.3.1.3.21 Date format drugstartdateformat, B.4.k.4.r.6 drugstartdate, Date format Product Lot # The product lot number O no template drugendateformat, B.4.k.4.r.7 drugendate The expiration date of the Medications Indication B.4.k.7.r.1 O drugindication **Expiration Date** 1.3.6.1.4.1.19376.1.5.3.1.3.21product Administered Medications The unique identifier for the B.4.k.4.r.9 NDC# or Unique ID drugbatchnumb O Lot# product Administered

Drug Safety Content CCD to E2B R3 Crosswalk Option-**Data Element Definition E2B R3 Description** E2B R3 Code **CCD Description CCD Code** ality Event Abated after use Indication that the event Medications stopped or dose resolved / abated after usage O expirationTime Administered reduced? stopped or dose reduced Indication if the reaction Event Reappeared after reoccurred after rechallenging Medications Code B.4.k.3.1 O drugauthorizationumb reintroduction? Administered 1.3.6.1.4.1.19376.1.5.3.1.3.21 the patient to the suspected substance Suspect Medical Brand name of the suspect O drugrecurreadministration no field no template Device Brand Name device Common Device Common name of the device O drugrecurreadministration no field no template Name Manuf. name, City and Manufacturer of the device O no template State Medical Device Model Model number of the device O no template

	Drug Safety Content CCD to E2B R3 Crosswalk									
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code				
Medical Device Catalog #	Catalog number of the device	О			no template					
Medical Device Serial #	Serial number of the device	О			no template					
Medical Device Lot #	Lot number of the device	0			no template					
Medical Device Other #	Other identifiers for the device	0			no template					
Operator of Device	The individual managing the device	0			no template					

	Drug Safety Content CCD to E2B R3 Crosswalk									
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code				
If implanted give date	Date of implantation of the device (if implanted)	О			no template					
If explanted give date	Date device was removed (if removed)	0			no template					
Is this a single use device that was reprocessed and reused on patient?	Indication if the device is a single-use device that was cleaned/reprocessed and is reused on the affected patient	0			no template					
Name and Address of Reprocessor	Name and address of the individual / organization reprocessing the single use device	0			no template					
Product available for evaluation?	Indication if the product is still available to be evaluated	0			no template					

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Date product returned to manuf.	If returned to the manufacturer, date of return	О			no template				
Concomitant Medical Products & Therapy Dates	Other medical products and treatment used proximal to the event	О			no template				
Signs and Symptoms	The signs and symptoms experienced by the patient	0			no template				
Symptom/ Illness Onset Date/Time	This is the range of time of which the problem was active for the patient; for PH: The date that the subject began having symptoms of condition being reported	0			Admission Medication	1.3.6.1.4.1.19376.1.5.3.1.3.20			
Patient Class	General type of patient, e.g., Inpatient, Outpatient, Emergency	0							

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Reporting Laboratory Identifier	Identifier for laboratory that is sending the result. This laboratory may be sending results received back from reference laboratories	О	reactionstartdateformat, reactionstartdate	date format , B.2.i.3					
Performing Laboratory	Laboratory that produced the test result. This may be a reference laboratory identifier.	0							
Report Date/Time	Date/time of report	0							

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Results Status	Status of report (preliminary, final, corrected)	О							
Ordered Test Code	The identifier code for the requested observation/test/battery	О							
Resulted Test	"The identifier code for the specific test component resulted	О							
Result Unit	Unit for numeric result context	О							
Test Interpretation	Interpretation of test result, including the susceptibility test interpretation	0							
Test Status	Status of the test result	С							

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Date of Test	The date that the laboratory test was performed for the subject of the Case Report.	O							
Test Method	Testing method used to arrive at the specific result :The name of the laboratory test.	О							
Test Result	The test result of the laboratory test including any applicable result units of measure	О	testdateformat, testdate	date format, B.3.r.b					
Specimen Collection Date	The date that the specimen for the laboratory test was taken from the subject of the Case Report	0							

	Drug Safety Content CCD to E2B R3 Crosswalk								
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code			
Source of Specimen	The physical body location from where the specimen for the lab report was taken from the subject	О	testresult	B.3.r.d2					
Name of Organization Collecting Specimen	Name of organization collecting specimen which may be different from the organization performing the laboratory analysis	О							
Diagnosis/Injury Code	Diagnosis or diagnoses assigned as a result of the encounter	О;							

Drug Safety Content CCD to E2B R3 Crosswalk						
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code
Diagnosis Type	Type of diagnosis being sent (admitting, working, final)	О				
Diagnosis Date/Time	The date that the subject of the Case Report was diagnosed with Condition above	О				
Previous Event Report Details	Definitions pending - see appendix for detail to be considered	О				
Reason for Non- Evaluation	Definitions pending - see appendix for detail to be considered	О				

Drug Safety Content CCD to E2B R3 Crosswalk						
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code
Type of Follow-Up	Definitions pending - see appendix for detail to be considered	О				
Type of Remedial Action	Definitions pending - see appendix for detail to be considered	О				
Administration of Treatment	Was treatment administered?	R				
Date of Admin of Treatment	The date treatment was administered. For HepB, Date HBV vaccine administered	R				
Name of Treatment	Name of the treatment	R				
Hospitalization	If the subject of the case report was hospitalized	R				

Drug Safety Content CCD to E2B R3 Crosswalk						
Data Element	Definition	Option- ality	E2B R3 Description	E2B R3 Code	CCD Description	CCD Code
Admission Date	Enter the date that the subject of the Case Report was Admitted to the hospital.	О				
Discharge Date	Enter the date that the subject of the Case Report was Discharged from the hospital	R				
Hospital Name	Name of hospital the case was admitted.	О				
Recovered	Did the subject recover from the disease?	R				
Death	Did the subject die as a result of the disease?	R				
Data Element	Definition	О	reactionoutcome	B.2.i.6		
Facility/ Importer Name	The name of the facility that the health care provider diagnosed the subject of the Case Report.	О	seriousnessdeath	B.2.i.2.2		

Appendix B: Triggers

Management of triggers for generating drug safety content

Triggers are generally managed within the EHR workflow to request from a clinician a determination as to whether or not an adverse event has occurred. Some triggers that have been used include:

- 1. In the EHR used in the ASTER project, a question each time a medication is discontinued for the ordering physician to enter if the discontinuation is due to an adverse event
- 2. Automated triggers based on specific medication orders or laboratory results or clinical events as listed in Minutes Drugs Safety Content Profile June 5, 2008
- 3. Regardless, triggers require clinician determination before a drug safety content report can be initiated and, therefore, triggers are the responsibility / expectation of the originating EHR.

Sources for triggers:

- 4. Institute for Healthcare Improvement [(IHI) http://www.ihi.org/ihi/workspace/tools/trigger/ ADE Trigger Tools]
- Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm, Qual Saf Health Care. 2003;12:194-200. - Lists 24 clinical triggers to identify potential adverse drug events. *** See Table Below for 24 Triggers
- 6. Resar RK, Rozich JK, Classen D. Methodology and rationale for the measurement of harm with trigger tools, Qual Saf Health Care. 2003;12:ii30-ii45.
- 7. Takata GS, Mason W, Taketomo C, Logsdon T and Sharek PJ. Development, Testing, and Findings of a Pediatric-Focused Trigger Tool to Identify Medication-Related Harm in US Children's Hospitals. Pediatrics 2008;121:927-935. Full Text of Article

Rozich, Haraden, Resar - Clinical Triggers3 Trigger # EHR Trigger Type (added) **Trigger** Concern Hypersensitivity reaction or drug T1 Diphenhydramine Order effect T2 Vitamin K Over-anticoagulation with warfarin Order T3 Flumazenil Oversedation with benzodiazepine Order T4 Droperidol Nausea/emesis related to drug use Order

Table B-1: Clinical Triggers

³ Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm, Qual Saf Health Care. 2003;12:194-200. - Lists 24 clinical triggers to identify potential adverse drug events.

Rozich, Haraden, Resar - Clinical Triggers3					
T5	Naloxone	Oversedation with narcotic	Order		
Т6	Antidiarrheals	Adverse drug event	Order		
Т7	Sodium polystyrene	Hyperkalemia related to renal impairment or drug effect	Order		
Т8	PTT >100 seconds	Over-anticoagulation with heparin	Result occurrence		
Т9	INR >6	Over-anticoagulation with warfarin	Result occurrence		
T10	WBC <3000 × 106/μl	Neutropenia related to drug or disease	Result occurrence		
T11	Serum glucose <50 mg/dl	Hypoglycemia related to insulin use	Result occurrence		
T12	Rising serum creatinine	Renal insufficiency related to drug use	Result occurrence (calculated delta)		
T13	Clostridium difficile positive stool	Exposure to antibiotics	Result occurrence (perhaps order for stool C difficile)		
T14	Digoxin level >2 ng/ml	Toxic digoxin level	Result occurrence		
T15	Lidocaine level >5 ng/ml	Toxic lidocaine level	Result occurrence		
T16	Gentamicin or tobramycin levels peak >10 μg/ml,trough >2 μg/ml	Toxic levels of antibiotics	Result occurrence		
T17	Amikacin levels peak >30 μg/ml, trough >10 μg/ml	Toxic levels of antibiotics	Result occurrence		
T18	Vancomycin level >26 µg/ml	Toxic levels of antibiotics	Result occurrence		
T19	Theophylline level >20 µg/ml	Toxic levels of drug	Result occurrence		
T20	Oversedation, lethargy, falls	Related to overuse of medication	Occurrence of finding/observation		
T21	Rash	Drug related/adverse drug event	Occurrence of finding/observation		
T22	Abrupt medication stop	Adverse drug event	Order to discontinue		
T23	Transfer to higher level of care	Adverse event	Order		
T24	Customized to individual institution	Adverse event	Local determinant Acronyms: PTT=prothrombin time; INR=international normalized ratio; WBC=white blood cells		

Retrieved from

"http://wiki.ihe.net/index.php?title=Minutes_Drugs_Safety_Content_Profile_June_5%2C_2008"

Volume 4 – National Extensions

Not applicable